Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ALIS In Wonderland: Insmed Reaches Fairy Tale Heights On Lung Disease Results

Executive Summary

Insmed will commercialize ALIS, its inhaled amikaycin formerly known as Arikayce, on its own for a rare, bacteria-driven lung disease if the company can win accelerated approval based on new Phase III results.

You may also be interested in...



Antibiotic Pipeline Profile: Targeting Delivery To Infection Site

Among the antibiotics that have garnered a qualified infectious disease product designation, a collection of late-stage products are targeted at local delivery, especially inhaled and vaginal formulations.

'What Is Microbiologic Success?': Rare Lung Infection Is Microcosm Of Antibiotic Development Challenges

FDA is working hard on expanded access program for patients with non-tuberculous mycobacterial (NTM) lung infections; there is no approved drug for the condition in part because of the difficulty in defining trial endpoints.

FDA: Ph III needed before Arikayce NDA; Insmed plummets

Shares of Insmed plunged 27% on 4 August after it disclosed the FDA said Phase III data would be needed to support a new drug application (NDA) for Arikayce (liposomal amikacin for inhalation), formerly known as Arikace, as a treatment for nontuberculous mycobacteria (NTM) lung infections, declaring the firm's single Phase II trial was not sufficient for an accelerated approval – especially since it missed its primary endpoint.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel